follyism and sfvictim - how did you hear about this stock?
It has the attention of Israeli media and is discussed regularly on Israeli stock forums, so here it's on the radar
Also in fourth quarter, a Phase 3 study will read out in a 231 patient study using CF101 in dry eye syndrome, which is being run by OphthaliX.
... buy” rating and $15 price target
“The primary stock driver should be the readout of a Phase 2b using CF101 in rheumatoid arthritis patients,” he said. “The company is taking some important lessons learned from previous studies and we believe is giving the study the best shot possible by prospectively identifying patients who have high expression levels of the CF101’s target (the A3A Receptor).”
Mr. Pantginis believes the data from this study will be positive and “act as a potential launching point to drive confidence in the drug and the overall platform in the U.S.”
IMUC management has visibility to events occurence (was elaborated previously) and reiterates that results will be in Q4 or Q1. It takes 3-4 months from 64th event to results. These 2 assumptions result in: (a) 64th event has happened in Aug- Sep; (b) results will be announced by Jan end
Sentiment: Strong Buy
Each one can make this baby explode.
"Before the end of 2013, we are scheduled to announce the results of our Phase II trials for CF101 in the treatment of rheumatoid arthritis and data from our Phase III trials of CF 101 for the treatment of dry eye syndrome, which is licensed to our subsidiary OphthaliX."
CF101's anti-inflammatory indications include psoriasis, for which the Company is now conducting Phase III trials in the U.S., Europe and Israel. The global market for treating psoriasis was $3.3 billion in 2010 and is projected to reach $6.7 billion by 2018, according to Global Data. Phase II trials are also being conducted for CF101 in the treatment of rheumatoid arthritis in the U.S., Europe and Israel, with results expected to be announced during the fourth quarter of 2013. Global Data estimates that the global market for rheumatoid arthritis therapeutics was $12 billion in 2010 and is projected to reach $18 billion by 2020
IMHO the last par should read:
"In my most scenario, I see the trial as not reaching its primary endpoint and resulting in a sell off led by the Twitter traders. I own a small position in the stock on the basis that I think there is much greater chance of the trial reaching its primary endpoint and perhaps quadrupling if my judgment is correct as opposed to complete failure that ends the development of ICT-107 and destroys much of the stock price. I want some exposure to this possibility. I think that the most likely outcome is an in between scenario that points to a path forward, but could have a short-term negative effect due to the Twitter traders. This could be the point at which I might significantly increase my position in the stock."